Research programme: cancer immunotherapeutics - Alligator Biosciences

Drug Profile

Research programme: cancer immunotherapeutics - Alligator Biosciences

Alternative Names: IMCAN

Latest Information Update: 11 Mar 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Alligator Bioscience
  • Class Monoclonal antibodies
  • Mechanism of Action CD40 antigen stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 06 Feb 2015 Alligator Bioscience plans a phase I trial for Solid tumours (Late-stage disease) in United Kingdom, Denmark, Sweden (NCT02379741)
  • 14 Jan 2014 Preclinical trials in Cancer in Sweden (Intratumoural) before Jan 2014
  • 08 Dec 2009 Alligator Bioscience secures patent protection for its FIND technology in Japan
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top